Mesa Labs Q2 revenue down 9.5% to $53.2M, net loss of $1.23M

MESA LABORATORIES INC /CO/

2024-Q2 EPS reported -$0.33 revenue$103,810,000

Operating income turned negative at $(60), down 101.5% vs prior year.
Non-GAAP adj. operating income ex unusual items fell 29.1% to $11.2M.
Clinical Genomics down 15.7% organic on Sema4 loss ($8.2M annual headwind).
Biopharm Development revenues fell 24.4% organic, consumables up 4.7%.
Cost actions expected to save ~$2M annually starting in Q3; GKE acquisition closed Oct 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MESA LABORATORIES INC /CO/ reported second fiscal quarter ended September 30, 2023 results: revenue $53,165, net income $(1,230), EPS $(0.23) per diluted share.

Period: second fiscal quarter ended September 30, 2023
Revenue: $53,165
Net income: $(1,230)
EPS: $(0.23) per diluted share
Result: reported results

Exact text from the filing

our Clinical Genomics division early in 3Q23 but was better than the first quarter for both revenues and AOI excluding unusual items. Total revenues for the second quarter were $53,165, which resulted in an organic revenue (“organic”) decline of 9.6% versus the same quarter in the prior year (“2Q23”), or a 5.0% sequential increase when compared to the first

View on SEC.gov

Browse all earnings releases →

MESA LABORATORIES INC /CO/ filing history →

Source: SEC EDGAR

accession 0001437749-23-030284

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.